Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy

Mory Nouriani, Afshin Bahador, Jonathan S. Berek, Joan P. Cheng, Dennis S. Chi, William A. Cliby, Giuseppe Del Priore, Mark K. Dodson, Bridgette D. Duggan, David M. Gershenson, Scott E. Lentz, Richard T. Penson, William R. Robinson, Mildred Rodriguez, Lynda D. Roman, Mimi C. Yu, Karen Zempolich, Louis Dubeau

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Purpose: We sought to test the hypothesis that the presence of telomerase activity in peritoneal washings of patients treated for ovarian carcinoma is a sensitive and specific indicator of the presence of residual disease. We hypothesized that this test, if added to second-look procedure protocols, could help determine whether residual disease is present or not in patients who have completed their adjuvant chemotherapy for ovarian carcinoma. Experimental Design: Peritoneal washings were obtained from 100 consecutive patients undergoing a second-look procedure after treatment for ovarian carcinoma (cases) and from 100 patients undergoing surgery for benign gynecological conditions (controls). The washings were assayed for telomerase activity using the telomerase repeat amplification protocol. The results were compared to the histological and cytological findings. Results: Among our 100 cases, 82 (82%) had either positive second-look procedures or expressed telomerase in their peritoneal washings. Fifty-three (53%) had positive second-look procedures, whereas 66 (66%) tested positive for telomerase. Twenty-nine of the 47 patients (62%) with negative second-look procedures tested positive for telomerase. Of the 53 patients with positive second-look procedures, 37 (70%) tested positive for telomerase. None of the 100 controls (0%) expressed telomerase in their peritoneal washings. Conclusions: Telomerase activity in peritoneal washings of patients treated for ovarian carcinoma and undergoing a second-look procedure may provide a means of increasing the sensitivity of such procedures for the detection of residual disease while maintaining a high level of specificity.

Original languageEnglish (US)
Pages (from-to)2681-2686
Number of pages6
JournalClinical Cancer Research
Volume10
Issue number8
DOIs
StatePublished - Apr 15 2004

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy'. Together they form a unique fingerprint.

  • Cite this

    Nouriani, M., Bahador, A., Berek, J. S., Cheng, J. P., Chi, D. S., Cliby, W. A., Del Priore, G., Dodson, M. K., Duggan, B. D., Gershenson, D. M., Lentz, S. E., Penson, R. T., Robinson, W. R., Rodriguez, M., Roman, L. D., Yu, M. C., Zempolich, K., & Dubeau, L. (2004). Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy. Clinical Cancer Research, 10(8), 2681-2686. https://doi.org/10.1158/1078-0432.CCR-0523-03